Comparative Pharmacology
Head-to-head clinical analysis: ENFLONSIA versus NITROUS OXIDE USP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENFLONSIA versus NITROUS OXIDE USP.
ENFLONSIA vs NITROUS OXIDE, USP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.
Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.
10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.
Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.
None Documented
None Documented
Terminal half-life 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment.
Terminal elimination half-life is 2–6 minutes (context-sensitive); rapid washout due to low blood solubility and high pulmonary elimination.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal elimination as metabolites.
Primarily eliminated via lungs as unchanged gas (>99% exhaled); negligible renal (<1%) or biliary/fecal elimination.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic